Case Study Of Genital Warts

Genital Warts Treatment Case Studies, Success Stories, and Reviews

Compiled by hand from TONS of e-mails, phone voice messages, and physical postal mail I’ve gotten from people over the years who treated their warts successfully with my report

I’ve gotten SO MANY comments from happy people over the years that I couldn’t possibly list them all on a single page or else no one would want to read it.

However, there are a few people out there who have told me they wish I would post as many comments from other people who have used my report as possible, because it gives them hope and encouragement for their own situation. And of course it’s always good to know other people are going through the exact same thoughts and feelings and you are not alone!

So this page is the first of what will be a growing number of linked pages over time showing as many reviews as I can post, as I get some free time once in awhile. These are in no particular order, although I did try to arrange the ones with voicemail messages on this first page to make them easier to find. And in a few cases where someone lived in a small town or had a very unique name, I had to change some identifying information because the person was getting hassled on Facebook by people trying to track them down. These people trust me with their privacy so please respect that.

This is the first page – page 2 is here

“…the cheapest most aggressive formula I’ve ever seen – it’s done wonders”

“Hey Greg, this is Lee. I had bought your report about a week and a half ago. It’s been working pretty good actually. I’ve been afflicted for about 6 years and I’ve tried everything and I have to admit I was real skeptical when I was searching the web last week. It’s done wonders – I’m sure I got to keep up with it though. I’ve tried everything; condylox, Aldara, I mean everything you can imagine. I’m excited, but like I said I’m sure it’s not like a 7 day wonder, I’m sure I’m going to have to keep up with it and keep alert and everything but it’s the most inexpensive yet most aggressive treatment I’ve seen. Anyways, I just want to say thanks – it’s a real story and I’m actually pleasantly surprised. Thanks a lot, bye.”

Greg’s Note: Lee said a lot more than what I reprinted above. You can listen to the voicemail below for his other comments that are too long to print here.

“…all my symptoms are GONE…”

“Greg — thank you very much for sharing this information with me. I’ve been searching all over the place trying to find answers and I’m very glad I ran across your site. All my symptoms are gone, and haven’t had any more problems for about a year now! If there’s anything I can do to help you with your site, let me know!”

Special Note: After I got Caleb’s e-mail, I asked him to call my number and leave a short voicemail so everyone could hear he is for real. Thank you for your help, Caleb!

“…after one week, my warts are gone…”

“…I just wanted to tell you I am so thankful. I’ve been doing this for a week and they’re gone. [My genital warts] went completely away. I feel like I’ve reclaimed part of my social life back. Thank you so much.”

Greg’s Note: I do not have a picture available for Henry, but he left a voicemail on my phone you can listen to below

“Your report really does work!”

“I found your site while researching information on genital warts because I had a really bad breakout for 2 months. I went to the doctor every single Tuesday and had them burnt off, but those treatments did NOTHING. I’d tried other genital warts treatments I heard about on the internet and I really didn’t expect your method to work either, but thank God I was wrong! Your report really does work!”

Note: This is a summary of what Connie told me. Click the play button below to listen to the voicemail she was kind enough to leave for me that tells her full story.

“My doctor said the warts were gone after your treatment – thank you!”

“Greg, hi, this is Tony from Phoenix Arizona. I don’t know if you got my e-mail or not but I just wanted to give you a call, and… I just wanted to say THANK YOU. Thank you, thank you, thank you! I went to the doctor today, got a clean bill of health – nothing there! Done! I told my doctor what I did and what I put on them and he looked at me like I was crazy but, hey, it worked! That’s ALL that matters. It worked. So thank you again and I’ll be in touch!”

Greg’s Note: This is a summary of what Tony told me in a voicemail he left on my phone. Click the play button below to listen to the whole thing in his own voice.

“The formula you have is absolutely unbelievable”

“Hi Greg this is Andrew calling again. I just want to thank you so very much. The formula you have is absolutely unbelievable. I’ve been on it for maybe 18 hours and I’ve already been able to wipe away 2 warts completely off. It’s absolutely amazing. So thank you so very much. If you ever have the chance to give me a phone call back, there’s a few more questions I would like to ask you but I am very super impressed and very very pleased so thank you for everything!”

“My genital warts were GONE in about 5 days”

“…[quoting the voicemail she left me, which you can listen to by clicking the play button below]… Greg, I’m Dianne in Atlanta, and I just HAVE to call and thank you personally for your genital warts treatment. I got your report last Saturday night on the internet and my warts are already GONE – and I can’t thank you enough. I sent you an email thanking you but I also wanted you to hear the voice of a real person telling you how much I appreciate it. I hope you’re having a wonderful, wonderful day. Thank you – bye bye.”

Greg’s Note: 5 days isn’t the normal amount of time it takes for most people to clear up their warts so Dianne’s phone call really impressed me. But it just depends on the person; some people are really fast at getting rid of their genital warts like I was and for other people it takes longer. Average time is 2 to 3 weeks for most cases.

“Your treatments worked for my nephew’s warts”

“Hey Greg this is Joseph from Denver – I just got in to say hello and also let you know that [your treatments] actually worked for my nephew. He’s very happy about it! I just wanted to have a conversation with you to see if you had some other suggestions for other ailments people have in that area. So let me know, give me a call anytime. I just want to thank you once more, my nephew is very very happy. Thank you!”

“I can see it drying out my warts already – this is fantastic”

Voicemail: “Greg, good afternoon over in America. This phone call comes from New Zealand. I am following your treatment and I’m having results already – very very good! I can see the results – I can see the warts are drying out and I can see exactly what the treatment is doing to them. It’s fantastic and thank you very much for sharing all this information. Goodbye.”

“Got rid of my genital wart breakout on the 7th day”

“I saw your website then I bought your ‘Genital Warts Report’ and tried method 1. It got rid of my breakout within 7 days. I applied it 2 times a day and on the 7th day I checked and it just disappeared. I was really surprised – it really worked! So if anyone out there is listening, this genital warts treatment – it really does work. Thanks a lot!”

Greg’s Note: Since James was kind enough to leave me a voicemail on my phone, I included his review up higher on this page with the other voicemails. I admit at first I thought his message was a little strange sounding, but I returned his call later where he told me he was kinda nervous when he left the message and wasn’t sure exactly what all to say while still maintaining his privacy.

“I’ll be able to sleep better tonight – thank you”

“Greg, hi I talked to you awhile ago and we talked about fordyce spots. I just found out for sure that’s what it is and I appreciate all your help. This’ll ease my mind and I’ll be able to sleep a little better tonight. Thank you.”

Greg’s Note: What Dave is referring to in the voicemail he left me is how my website helped him determine he had fordyce spots instead of genital warts. After he confirmed it, he called and left me this message.

“You’re really doing a great service for people here”

“We talked a few days ago about some bumps on my penis I thought were genital warts but it turns out that’s not what they were after all. My doctor said it turned out to be some type of skin tag as you suggested might be the case. I do want to thank you for your help though and if I do ever get HPV or warts you are definitely the first person I’m going to call. Thanks for your help and for the talk. You’re really doing a great service for people here.”

Greg’s Note: After listening to Jordan’s issue, I suggested he get it checked out at the doctor since what he was describing didn’t sound like HPV warts to me. Thankfully that was the case and he could finally put his mind at ease after a couple weeks of freaking out!

**** GO HERE FOR PAGE 2 WITH MORE REVIEWS ****

“Your report worked totally 100% – completely saved me”

“When I was diagnosed with genital warts, it RUINED MY LIFE. My confidence was lowered and my interactions with people weren’t as good and I just felt terrible about myself. I reached a point where I was willing to do WHATEVER IT TOOK to get rid of this and that’s when I started searching around and came across your website. At first I was like “oh you know this is probably a scam or whatever” but I was so sick of going to the doctors and getting my skin burned and having it leave scars and so much pain. And I was willing to whatever it took, so I downloaded your report and saw how easy it was. A little over 24 hours later, it was COMPLETELY gone. I am SO GLAD I did it. I am so glad you put this information out there and I wanted to thank you so much!”

Greg’s Note: Chrissy left a voicemail on my phone you can listen to below – even I was surprised at the time it took her warts to go away – 24 hours is NOT normal but with some people it can happen!

Abstract

Objective. To asses the burden and correlates of genital warts in women.

Methods. We conducted a population-based cross-sectional study in 69,147 women (18–45 years of age) randomly chosen from the general population in Denmark, Iceland, Norway, and Sweden. Information on clinically diagnosed genital warts and lifestyle habits was collected using a questionnaire.

Results. Overall, 10.6% reported ever having had clinically diagnosed genital warts. In addition, 1.3% reported having experienced genital warts within the past 12 months. The cumulative incidence for different birth cohorts, estimated on the basis of age at first diagnosis of genital warts, increased with each subsequent younger birth cohort (P<.01). The lifetime number of sex partners was strongly correlated with a history of genital warts (odds ratio for ⩾15 partners vs. 1 partner, 9.45 [95% confidence interval, 7.89–11.30]). The likelihood of reporting genital warts also increased with a history of sexually transmitted disease, use of hormonal contraceptives, use of condoms, smoking, and higher education.

Conclusions. The data suggest that ∼1 in 10 women in the Nordic countries experience genital warts before the age of 45 years, with an increasing occurrence in younger birth cohorts. These data are important for developing and evaluating strategies (e.g., human papillomavirus [HPV] vaccination) to control and prevent HPV infection and disease in the population.

Genital human papillomavirus (HPV) infection is the most common viral sexually transmitted infection (STI). The pathogenetic spectrum of genital HPV infections is broad, ranging from cancer to genital warts. Even though a condition with genital warts is not life-threatening, these lesions can cause clinical symptoms, such as burning, itching, bleeding, and pain. A diagnosis of genital warts can also cause psychosocial stress, resulting in decreased self-esteem, negative self-perception, embarrassment, and anxiety [1, 2]. Although the HPV types associated with genital warts (HPV-6 and HPV-11 account for ∼90% of episodes) may not cause cervical cancer, women with a history of genital warts have been shown to have an increased risk of cervical intraepithelial neoplasia (CIN) and cancer [3, 4], which is most likely explained by a higher risk of having other, carcinogenic HPV types.

Genital warts represent not only a health problem for the individual but also an economic burden for society. One study of genital warts among privately insured individuals estimated an annual cost of $140 million for US private health plans in relation to the diagnosis and treatment of genital warts [5]. Results from a recent study estimated a cost of £10.1 million for managing incident cases of genital warts only in 2003 in the United Kingdom [6].

Several studies have suggested that HPV infection, including infection with HPV-6 and HPV-11, is a major and most likely increasing problem [7–9]. However, the majority of studies of the prevalence and incidence of genital warts have been conducted in selected populations, such as sexually transmitted disease (STD) clinic attendees, university students, or individuals insured through private health plans [5, 10–12]. Thus, few data have originated from general population studies [13, 14]. As a result, knowledge about the overall and dynamic occurrence of genital warts across different birth cohorts in the female population is limited. Such data are important for developing and evaluating strategies to control and prevent HPV infection and disease (e.g., genital warts) in the population. Given that a prophylactic vaccine against HPV-16, -18, -6, and -11 has recently become publicly available in many countries, establishing and understanding the burden of genital warts at the general population level can inform vaccine policy decisions.

The overall aim of the present study was to assess the occurrence and correlates of genital warts in random samples of the general female population in the 4 Nordic countries.

Subjects, Materials, and Methods

Study population. In each of the 4 countries (Denmark, Iceland, Norway, and Sweden), each citizen has a unique personal identification number (PIN), comprising information about sex and date of birth. These PINs are registered in a national, computerized central population registry in each country, together with information on vital status, migration, and current address on the individual level. By use of these computerized population registries, which cover the entire population in the respective country, a random sample of women (18–45 years of age) was drawn from the general female population in each country, using the PIN as the key identifier. Informed consent was obtained from each study participant. The study was approved in each country by the data protection board and the scientific ethics committee.

Our goal was to include at least 14,000 women in each country. A priori, we anticipated an overall response rate of 50%–60%, implying that ∼25,000–28,000 women in each country should be invited for the study. The final number of invited women in each country was mostly dependent on what was logistically feasible in the respective country.

From November 2004 to June 2005, a total of 28,000 women were invited to participate in both Denmark and Iceland, whereas 25,001 women and 25,000 women were invited from Norway and Sweden, respectively (1 extra woman was erroneously drawn from Norway). Women who had moved or emigrated, who had died before our contact, or who did not speak the respective Nordic language were ineligible for the study, leaving 27,272 Danish women, 27,548 Icelandic women, 24,424 Norwegian women, and 24,689 Swedish women as potential participants. A total of 1737 Danish women, 422 Icelandic women, 2409 Norwegian women, and 1661 Swedish women explicitly stated that they did not want to participate in the study, whereas no response was obtained from 3336 Danish women, 12,075 Icelandic women, 5411 Norwegian women, and 7315 Swedish women. Thus, we recruited for the study 22,199 Danish women (participation rate, 81.4%), 15,051 Icelandic women (54.6%), 16,604 Norwegian women (68.0%), and 15,713 Swedish women (63.6%), for a total of 69,567 women. We excluded 81 women who had incomplete questionnaires or a discrepancy between their PIN and the year of birth reported, such that the population in this study consisted of 69,486 women (22,173 from Denmark, 15,025 from Iceland, 16,575 from Norway, and 15,713 from Sweden). For this article, we excluded 339 women who did not answer the question about genital warts; consequently, a total of 69,147 women were available for the present analysis.

Data collection. To guarantee confidentiality for the participants, all invited women were appointed a unique study number by the national study centers. An invitation letter and a self-administered structured questionnaire were mailed to each woman in Denmark, Iceland, and Norway. It was also possible to answer the questions by means of a Web-based questionnaire, which could be accessed using the unique study number and a personal access code, which were provided in the invitation letter (in Sweden, this was initially the only option). In all 4 countries, women who did not respond within 3–4 weeks received a reminder, including the questionnaire, by postal mail. For those who still did not respond, either the women were contacted by phone and reminded about the study (Iceland) or a telephone interview was conducted whenever possible (Denmark, Norway, and Sweden). The telephone interview comprised the same questions as those included in the self-administered paper-or Web-based questionnaire.

Via the survey, we obtained information on sociodemographic variables as well as on smoking history, alcohol intake, reproductive history, contraceptive use, and sexual habits. In addition, we collected information on ever having had a clinical diagnosis of genital warts, genital warts during the previous 12 months, age at first diagnosis of genital warts, and previous episodes of other STIs (genital chlamydial infection, gonorrhea, genital herpes, and trichomoniasis).

Statistical analysis. Correlates of self-reported genital warts were examined using univariate and multiple logistic regression, by which odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were estimated. Variables were selected on the basis of the current literature. The multivariate analysis was initially performed separately for each country; however, because the results were very similar (data not shown), we included all 4 countries in 1 analysis, adjusting for country in the final statistical model. We also examined the results restricted to each mode of response (i.e., paper-based questionnaire, Web-based questionnaire, and telephone interview), but, because we found no substantial differences in the overall results according to mode of response, only the combined analysis is presented here.

On the basis of information on age at first diagnosis of genital warts, the cumulative incidence of having had genital warts up to a certain age was estimated by means of the life table (actuarial) method, stratified by country and birth cohort.

Results

Denmark provided the highest proportion of women (32%), followed by Norway (23.9%), Sweden (22.5%), and Iceland (21.6%). table 1 shows the distribution of mode of response by country, with Iceland and Sweden having the highest proportion of women responding by means of the Web-based questionnaire and Denmark and Norway having the highest proportion responding by mail.

Nearly 8% of the women in the overall study population were 20 years of age or younger, with 16%–20% in each of the subsequent 5-year age groups and the age distribution being similar in the 4 countries (mean age, 31.8 years for Denmark, 32.2 years for Iceland, 31.2 years for Norway, and 32.2 years for Sweden). The majority of the women were married or cohabiting (69.6%). The median lifetime number of sex partners was 5 and the median age at first intercourse was 16 years. A little more than 1 in 5 women reported ever having had an STD other than genital warts (data not shown).

A total of 7351 women (10.6%) reported having had at least 1 previous episode of clinically diagnosed genital warts, and 912 women (1.3%) had experienced genital warts during the past 12 months (data not shown). The prevalence of ever having had genital warts ranged from 12.0% (95% CI, 11.5%–12.6%) in Iceland to 9.5% (95% CI, 9.0%–9.9%) in Norway (table 2). The same pattern was reflected in the mean lifetime number of sex partners, for which Icelandic women and Norwegian women had, respectively, the highest (8.8) and the lowest (7.4) mean lifetime number of sex partners. Icelandic women also had the lowest mean age at first diagnosis of genital warts (21.3 years), whereas the Norwegian women had the highest mean age at first diagnosis of genital warts (22.7 years), with Denmark and Sweden in between (21.9 years).

Table 2.

Selected characteristics with regard to sexual habits and genital warts in the 4 Nordic countries.

Table 2.

Selected characteristics with regard to sexual habits and genital warts in the 4 Nordic countries.

We examined the proportion of women reporting having had genital warts during the past 12 months in relation to age of the women at enrollment in the study, and the same picture emerged in all 4 countries—namely, a decreasing proportion of women with genital warts during the past 12 months with increasing age (figure 1). The proportions for all 4 countries were similar from ages 26 to 45 years, whereas younger Icelandic women were much more likely to report genital warts during the past 12 months (4.7% vs. ∼2% in the other 3 countries).

Figure 1.

Proportion of self-reported clinically diagnosed genital warts during the past 12 months, by age and country

Figure 1.

Proportion of self-reported clinically diagnosed genital warts during the past 12 months, by age and country

In figure 2A, the cross-sectional proportion of women reporting ever having had clinically diagnosed genital warts according to birth cohort is presented for each country. For Iceland, Norway, and Sweden, the prevalence initially increased with increasing birth cohort. However, for older birth cohorts, a lower prevalence of having had genital warts was observed. In contrast, a continuously increasing prevalence with increasingly older birth cohorts was found among Danish women. Icelandic women born after 1973 reported a much higher prevalence of genital warts than in any other country (figure 2A). Sexual activity in terms of mean lifetime number of sex partners by birth cohort in the different Nordic countries (figure 2B) mirrored the picture observed for the age-specific prevalence of genital warts. We observed a tendency, most pronounced for Iceland, for younger birth cohorts to report more partners than older cohorts, with the exception of women in the youngest birth cohort, who had not yet accumulated that many partners. The pattern differed in Denmark, where the number of partners remained constant for the birth cohorts born in 1974 or before.

Figure 2.

Prevalence of self-reported clinically diagnosed genital warts (A) and mean lifetime no. of sex partners (B) among 69,147 women 18–45 years of age, by birth cohort and country.

Figure 2.

Prevalence of self-reported clinically diagnosed genital warts (A) and mean lifetime no. of sex partners (B) among 69,147 women 18–45 years of age, by birth cohort and country.

table 3 displays correlates associated with a history of clinically diagnosed genital warts. We found that the most important factor was the lifetime number of sex partners (OR for ⩾15 partners compared with 1 partner, 9.45 [95% CI, 7.89–11.30]). Other important correlates included older age and a history of other STIs. In addition, use of hormonal contraceptives, condom use, ever having had an abortion, more education, and smoking for >59 pack-years increased the probability of reporting genital warts. In contrast, a history of genital warts was not strongly correlated with marital status (data not shown), age at first sexual intercourse, number of births, and alcohol intake after adjusting for other risk factors. The analysis of correlates associated with the risk of genital warts was also performed separately for each country, but only the analysis for all 4 countries combined is shown, because the results were similar for all countries. In addition, the overall results did not vary according to the way the women responded (data not shown).

0 thoughts on “Case Study Of Genital Warts

Leave a Reply

Your email address will not be published. Required fields are marked *